160 related articles for article (PubMed ID: 38388961)
1. RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.
Guo Y; Chai B; Zhang H; Chai X; Chen Y; Xu J; Qin L; Chai Y
Biol Direct; 2024 Feb; 19(1):15. PubMed ID: 38388961
[TBL] [Abstract][Full Text] [Related]
2. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
[TBL] [Abstract][Full Text] [Related]
3. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
4. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
5. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
6. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
[TBL] [Abstract][Full Text] [Related]
7. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
8. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
9. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
Fan M; Chen Z; Shao W; Chen Y; Lin Z; Yi C; Li Y; Lu L; Zhou Y; Lin J
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1479-1486. PubMed ID: 37434430
[TBL] [Abstract][Full Text] [Related]
10. WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.
Han WY; Wang J; Zhao J; Zheng YM; Chai XQ; Gao C; Cai JB; Ke AW; Fan J; Gao PT; Sun HX
Cancer Lett; 2023 Aug; 568():216259. PubMed ID: 37279851
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
Hu Q; Hu X; Zhang L; Zhao Y; Li L
Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
[TBL] [Abstract][Full Text] [Related]
12. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
Guo J; Zhao J; Xu Q; Huang D
BMC Cancer; 2023 Oct; 23(1):967. PubMed ID: 37828435
[TBL] [Abstract][Full Text] [Related]
13. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit.
Chen Z; Ma Y; Guo Z; Song D; Chen Z; Sun M
Ann Hepatol; 2022; 27(2):100669. PubMed ID: 35045360
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
[TBL] [Abstract][Full Text] [Related]
16. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
17. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
18. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
19. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Kim JJ; McFarlane T; Tully S; Wong WWL
Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
